Kamada Ltd. (KMDA) News

Kamada Ltd. (KMDA): $5.17

-0.08 (-1.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter KMDA News Items

KMDA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest KMDA News From Around the Web

Below are the latest news stories about Kamada Ltd that investors may wish to consider to help them evaluate KMDA as an investment opportunity.

$23.37 Million in Sales Expected for Kamada Ltd. (NASDAQ:KMDA) This Quarter

Wall Street brokerages forecast that Kamada Ltd. (NASDAQ:KMDA) will report sales of $23.37 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Kamada’s earnings. The lowest sales estimate is $22.24 million and the highest is $24.50 million. Kamada reported sales of $31.54 million during the same quarter last […]

Transcript Daily | December 13, 2021

Analysts Anticipate Kamada Ltd. (NASDAQ:KMDA) to Post $0.02 Earnings Per Share

Equities analysts expect that Kamada Ltd. (NASDAQ:KMDA) will announce $0.02 earnings per share for the current quarter, according to Zacks. Two analysts have issued estimates for Kamadas earnings. The highest EPS estimate is $0.04 and the lowest is ($0.01). Kamada reported earnings of $0.04 per share in the same quarter last year, which suggests a []

Dakota Financial News | December 9, 2021

Analysts Expect Kamada Ltd. (NASDAQ:KMDA) Will Post Quarterly Sales of $23.37 Million

Wall Street analysts predict that Kamada Ltd. (NASDAQ:KMDA) will post $23.37 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Kamadas earnings, with estimates ranging from $22.24 million to $24.50 million. Kamada posted sales of $31.54 million during the same quarter last year, which would indicate []

Dakota Financial News | December 6, 2021

Kamada Ltd. (NASDAQ:KMDA) Short Interest Down 21.3% in November

Kamada Ltd. (NASDAQ:KMDA) saw a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 546,800 shares, a drop of 21.3% from the October 31st total of 695,200 shares. Based on an average daily volume of 49,200 shares, the days-to-cover ratio is presently 11.1 days. Currently, []

Dakota Financial News | December 5, 2021

Kamada (NASDAQ:KMDA) Downgraded to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Kamada (NASDAQ:KMDA) from a hold rating to a sell rating in a research note released on Wednesday, Zacks.com reports. According to Zacks, Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and []

Dakota Financial News | November 28, 2021

Kamada (NASDAQ:KMDA) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Kamada (NASDAQ:KMDA) in a research note issued to investors on Tuesday, Zacks.com reports. Other analysts have also recently issued reports about the company. Zacks Investment Research upgraded Kamada from a sell rating to a hold rating in a research report on Wednesday, October 13th. TheStreet cut [] The post Kamada (NASDAQ:KMDA) Receives Buy Rating from HC Wainwright appeared first on ETF Daily News .

ETF Daily News | November 27, 2021

Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Kamada (KMDA) and Verastem (VSTM)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Universal Health (UHS – Research Report), Kamada (KMDA – Research Report) and Verastem (VSTM – Research Report) with bullish sentiments. Universal Health (UHS) In a report released yesterday, Ann Hynes from Mizuho Securities reiterated a Buy rating on Universal Health, with a price target of $151.00. The company's shares closed last Monday at $127.23, close to its 52-week low of $121.23. According to TipRanks.

Howard Kim on TipRanks | November 23, 2021

Kamada (NASDAQ:KMDA) Announces Earnings Results

Kamada (NASDAQ:KMDA) issued its earnings results on Sunday. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05), MarketWatch Earnings reports. Kamada had a return on equity of 6.73% and a net margin of 10.42%. During the same period last year, the firm posted $0.15 […]

Dakota Financial News | November 23, 2021

Kamada (NASDAQ:KMDA) Releases Earnings Results, Misses Expectations By $0.05 EPS

Kamada (NASDAQ:KMDA) released its quarterly earnings data on Sunday. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05), MarketWatch Earnings reports. Kamada had a net margin of 10.42% and a return on equity of 6.73%. During the same period in the prior year, the […]

Transcript Daily | November 23, 2021

Kamada Stock Jumps After Acquisition Of Four Plasma-Derived Products

Kamada Ltd (NASDAQ: KMDA ) has acquired four FDA-approved plasma-derived hyperimmune commercial products from Saol Therapeutics . Kamada will pay Saol a $95 million upfront payment and an additional $50 million in sales milestones during 2022-2034. The combined annual global revenue of the acquired portfolio in 2021 is expected to be $40 million - $45 Full story available on Benzinga.com

Benzinga | November 22, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5178 seconds.